Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?

Bibliography

• Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2012;375:1388-402
   Web of Science ®Google Scholar
• Higuchi MdL, Benvenuti LA, Martins Reis M, et al. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res 2003;60:96-107
   PubMed Web of Science ®Google Scholar
• Tanowitz HB, Kirchhoff LV, Simon D, et al. Chagas' disease. Clin Microbiol Rev 1992;5:400-19
   PubMed Web of Science ®Google Scholar
• Pinto Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med 2006;144:772-4
   PubMed Web of Science ®Google Scholar
• Pereira KS, Schmidt FL, Guaraldo AM, et al. Chagas' disease as a foodborne illness. J Food Prot 2009;72:441-6
   PubMed Web of Science ®Google Scholar
• Coura JR, Borges-Pereira J. Chagas disease: what is known and what should be improved: a systemic review. Rev Soc Bras Med Trop 2012;45:286-96
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006;6:583-7
   Google Scholar
• Salomon CJ. First century of chagas' disease: an overview on novel approaches to nifurtimox and benznidazole delivery systems. J Pharm Sci 2012;101:888-94
   PubMed Web of Science ®Google Scholar
• Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011;364:2527-34
   PubMed Web of Science ®Google Scholar
• Prata A. Chagas' disease. Infect Dis Clin North Am 1994;8:61-76
   PubMed Web of Science ®Google Scholar
• Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005;36:123-9
   PubMed Web of Science ®Google Scholar
• Sartori AMC, Ibrahim KY. Nunes et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 2007;101:31-50
   PubMed Web of Science ®Google Scholar
• Aufderheide AC, Salo W, Madden M, et al. A 9,000-year record of Chagas' disease. Proc Natl Acad Sci USA 2004;101:2034-9
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Tarleton RL. Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov 2011;6:653-61
   PubMed Web of Science ®Google Scholar
• Bastien J. The kiss of keath: Chagas' disease in the Americas. Univ. of Utah Press; Salt Lake City: 1998
   Google Scholar
• Second report of the WHO expert committee on the control of Chagas disease. World Health Organization; WHO Technical Report Series, No. 905 Press Release; Geneva; 2002. p. 85. Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=10&codcch=905#.
   Google Scholar
• World Health Organization (WHO), 2010. Chagas disease: Control and Elimination. UNDP/World Bank/WHO. They post their annual reports at: http://www.who.int/topics/chagas_disease/en/
   Google Scholar
• Urbina JA. Parasitological cure of Chagas disease: is it possible? Is it relevant? Mem Inst Oswaldo Cruz 1999;94:349-55
   PubMed Web of Science ®Google Scholar
• Tarleton RL, Zhang L, Downs MO. “Autoimmune rejection” of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. Proc Natl Acad Sci USA 1997;94:3932-7
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Armenti H, et al. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 1994;127:151-62
   PubMed Web of Science ®Google Scholar
• Andrade SG, Stocker-Guerret S, Pimentel AS, et al. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz 1991;86:187-200
   PubMed Web of Science ®Google Scholar
• Kaplan D, Ferrari I, Bergami PL, et al. Antibodies to ribosomal P proteins of Trypanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. Proc Natl Acad Sci USA 1997;94:10301-6
   PubMed Web of Science ®Google Scholar
• Docampo R, Schmuñis GA. Sterol biosynthesis inhibitors: potential chemotherapeutics against chagas disease. Parasitol Today 1997;13:129-30
   PubMedGoogle Scholar
• Leslie M. Drug developers finally take aim at a neglected disease. Science 2011;333:933-5
   PubMed Web of Science ®Google Scholar
• Tarleton RL, Reithinger R, Urbina JA, et al. The challenges of Chagas disease - grim outlook or glimmer of hope? PLoS Med 2007;4:e332
   PubMed Web of Science ®Google Scholar
• Klein N, Hurwitz I, Durvasula R. Globalization of Chagas disease: a growing concern in nonendemic countries. Epidemiol Res Int 2012;Article ID 136793:1-13
   Google Scholar
• Hotez PJ. Neglected infections of poverty in the United States of America. PLoS Negl Trop Dis 2008;2:e256
   PubMed Web of Science ®Google Scholar
• Hanford EJ, Zhan FB, Lu Y, et al. Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc Sci Med 2007;65:60-79
   PubMed Web of Science ®Google Scholar
• Bern C, Kjos S, Yabsley MJ, et al. Trypanosoma cruzi and Chagas' disease in the United States. Clin Microbiol Rev 2011;24:655-81
   PubMed Web of Science ®Google Scholar
• Esch KJ, Petersen CA. Transmission and epidemiology of zoonotic protozoal diseases of companion animals. Clin Microbiol Rev 2013;26:58-85
   PubMed Web of Science ®Google Scholar
• Barry MA, Weatherhead JE, Hotez PJ, et al. Childhood parasitic infections endemic to the United States. Pediatr Clin North Am 2013;60:471-85
   PubMed Web of Science ®Google Scholar
• Barry MA, Bezek S, Serpa JA, et al. Neglected infections of poverty in Texas and the rest of the United States: management and treatment options. Clin Pharmacol Ther 2012;92:170-81
   PubMed Web of Science ®Google Scholar
• Coura JR, Viñas PA. Chagas disease: a new worldwide challenge. Nature 2010;465:S6-7
   PubMed Web of Science ®Google Scholar
• Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010;115:14-21
   PubMed Web of Science ®Google Scholar
• Basile L, Jansa JM, Carlier Y, et al. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill 2011;16:1-10
   Google Scholar
• Mady C, Ianni BM, de Souza JLJ. Benznidazole and Chagas disease: can an old drug be the answer to an old problem? Expert Opin Investig Drugs 2008;17:1427-33
   PubMed Web of Science ®Google Scholar
• Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003;S1:S19-39
   Google Scholar
• Mejia AM, Hall BS, Taylor MC, et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J Infect Dis 2012;206:220-8
   PubMed Web of Science ®Google Scholar
• Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008;105:5022-7
   PubMed Web of Science ®Google Scholar
• Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 1987;81:755-9
   PubMed Web of Science ®Google Scholar
• Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006;8:471-9
   Google Scholar
• Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. A nonrandomized trial. Ann Intern Med 2006;144:724-34
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Trunz BB, Bloomer WD, et al. Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-Chagasic agents. J Med Chem 2011;54:8214-23
   PubMed Web of Science ®Google Scholar
• Bennett JE. Chemotherapy of systemic mycoses. N Engl J Med 1974;290:320-3
   PubMed Web of Science ®Google Scholar
• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10.101-10
   Google Scholar
• Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010;9:719-27
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). Adv Parasitol 2011;75:65-87
   PubMed Web of Science ®Google Scholar
• Correia MA, Ortiz de Montellano PR. Inhibition of cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry. Plenum Publishing Corp; New York: 2005. p. 246-322
   Google Scholar
• Vanden Bossche H. editor. Mode of action of pyridine, pyrimidine and azole antifungals. Ellis Horwood; Chichester: 1988. p. 79-119
   Google Scholar
• Roberts CW, McLeod R, Rice DW, et al. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 2003;126:129-42
   PubMed Web of Science ®Google Scholar
• Docampo R, Moreno SN, Turrens JF, et al. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol Biochem Parasitol 1981;3:169-80
   PubMed Web of Science ®Google Scholar
• McCabe RE, Remington JS, Araujo FG. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J Infect Dis 1984;150:594-601
   PubMed Web of Science ®Google Scholar
• Brener Z, Cançado JR, Galvao LM, et al. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz 1993;88:149-53
   PubMed Web of Science ®Google Scholar
• McCabe RE, Remington JS, Araujo FG. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg 1986;35:280-4
   PubMed Web of Science ®Google Scholar
• Apt W, Aguilera X, Arribada A, et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am J Trop Med Hyg 1998;59:133-8
   PubMed Web of Science ®Google Scholar
• Apt W, Arribada A, Zulantay I, et al. Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up. J Antimicrob Chemother 2013;68(9):2164-9
   PubMed Web of Science ®Google Scholar
• Campos R, Amato Neto V, Moreira AA, et al. Evaluation of the therapeutic activity of fluconazole in acute experimental infection caused by Trypanosoma cruzi. Rev Hosp Clin Fac Med Sao Paulo 1992;47:174-5
   PubMedGoogle Scholar
• Lepesheva GI, Ott RD, Hargrove TY, et al. Sterol 14 alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem Biol 2007;14:1283-93
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Zaitseva NG, Nes WD, et al. CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. J Biol Chem 2006;281:3577-85
   PubMed Web of Science ®Google Scholar
• Gulin JEN, Eagleson MA, Postan M, et al. Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection. J Antimicrob Chemother 2013;68:888-94
   PubMed Web of Science ®Google Scholar
• Urbina JA. New insights in Chagas' disease treatment. Drug Fut 2010;35:409-19
   Web of Science ®Google Scholar
• Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010;115:55-68
   PubMed Web of Science ®Google Scholar
• Urbina JA, Payares G, Molina J, et al. Cure of short- and long-term experimental Chagas' disease using D0870. Science 1996;273:969-71
   PubMed Web of Science ®Google Scholar
• Williams KJ, Denning DW. Termination of development of D0870. J Antimicrob Chemother 2001;47:720-1
   PubMed Web of Science ®Google Scholar
• Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010;54:2979-86
   PubMed Web of Science ®Google Scholar
• Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2009;104(Suppl 1):311-18
   PubMedGoogle Scholar
• Dobish MC, Villalta F, Waterman MR, et al. Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease. Org Lett 2012;14:6322-5
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Espinosa G, Gallego M, et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010;82:583-7
   PubMed Web of Science ®Google Scholar
• Clayton J. Chagas disease: pushing through the pipeline. Nature 2010;465:S12-15
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Hargrove TY, Anderson S, et al. Structural insights into inhibition of sterol 14 alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 2010;285:25582-90
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Park HW, Hargrove TY, et al. Crystal structures of Trypanosoma brucei sterol 14 alpha-demethylase and implications for selective treatment of human infections. J Biol Chem 2010;285:1773-80
   PubMed Web of Science ®Google Scholar
• Hargrove TY, Wawrzak Z, Liu J, et al. Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14α-demethylase (CYP51) from Leishmania infantum. J Biol Chem 2011;286:26838-48
   PubMed Web of Science ®Google Scholar
• Lepesheva G, Hargrove T, Kleshchenko Y, et al. CYP51: a major drug target in the cytochrome P450 superfamily. Lipids 2008;43:1117-25
   PubMed Web of Science ®Google Scholar
• Hargrove TY, Wawrzak Z, Liu J, et al. Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol. J Lipid Res 2012;53:311-20
   PubMed Web of Science ®Google Scholar
• Konkle ME, Hargrove TY, Kleshchenko YY, et al. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14 alpha-demethylase. J Med Chem 2009;52:2846-53
   PubMed Web of Science ®Google Scholar
• Villalta F, Dobish MC, Nde PN, et al. VNI cures acute and chronic experimental Chagas disease. J Infect Dis 2013;208:504-11
   PubMed Web of Science ®Google Scholar
• Andriani G, Amata E, Beatty J, et al. Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. J Med Chem 2013;56:2556-67
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr Top Med Chem 2011;11:2060-71
   PubMed Web of Science ®Google Scholar
• Hargrove TY, Kim K, de Nazaré Correia Soeiro M, et al. CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. Int J Parasitol Drugs Drug Resist 2012;2:178-86
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006;8:E101-11
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta 2007;1770:467-77
   PubMed Web of Science ®Google Scholar
• Molina J, Brener Z, Romanha AJ, et al. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J Antimicrob Chemother 2000;46:137-40
   PubMed Web of Science ®Google Scholar
• Molina J, Martins-Filho O, Brener Z, et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000;44:150-5
   PubMed Web of Science ®Google Scholar
• Soeiro MdNC, de Souza EM, da Silva CF, et al. Antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 2013;57(9):4151-63
   PubMed Web of Science ®Google Scholar
• Kawashita SY, Sanson GFO, Fernandes O, et al. Maximum-likelihood divergence date estimates based on rRNA gene sequences suggest two scenarios of Trypanosoma cruzi intraspecific evolution. Mol Biol Evol 2001;18:2250-9
   PubMed Web of Science ®Google Scholar
• Benaim G, Sanders JM, Garcia-Marchán Y, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006;49:892-9
   PubMed Web of Science ®Google Scholar
• Soeiro MN, de Castro SL. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin Ther Targets 2009;13:105-21
   PubMed Web of Science ®Google Scholar
• Soeiro MNC, Werbovetz K, Boykin DW, et al. Novel amidines and analogues as promising agents against intracellular parasites: a systematic review. Parasitology 2013;140:929-51
   PubMed Web of Science ®Google Scholar
• Chatelain E, Ioset JR. Drug discovery and development for neglected diseases: the DNDi model. Drug Des Devel Ther 2011;5:175-81
   PubMed Web of Science ®Google Scholar
• Keenan M, Abbott MJ, Alexander PW, et al. Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease. J Med Chem 2012;55:4189-204
   PubMed Web of Science ®Google Scholar
• Hargrove TY, Wawrzak Z, Alexander P, et al. T. cruzi CYP51 complexes with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen-selectivity. J Biol Chem 2013. [Epub ahead of print]
   PubMedGoogle Scholar